Insilico Medicine Mediaroom - PR Newswire APAC

Insilico Open-Sources 24/7 Personal Longevity Superintelligence to Turn Quantified-Self Data into Predictive Health States and Aging Research

CAMBRIDGE, Mass., Nov. 6, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage generative AI dr...

2026-11-06 22:00 6013

Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026

CAMBRIDGE, Mass., Oct. 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clini...

2026-10-26 21:00 5785

Insilico Medicine and Servier Achieve First Milestone in AI-Driven R&D Collaboration, Triggering An undisclosed Milestone Payment

* Two programs under the multi-year R&D collaboration have initiated and completed target nominat...

2026-10-20 21:00 3911

AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases

* Sustained Boost in AI-Driven R&D Productivity: ISM9546 marks Insilico Medicine's 35th preclinic...

2026-10-13 21:00 4112

Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist

CAMBRIDGE, Mass., Sept. 30, 2026 /PRNewswire/ -- As population aging accelerates with demand for we...

2026-09-30 13:57 1669

Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study

The paper introduces three interconnected resources for the global scientific community: * Longe...

2026-09-17 23:21 4087

Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks

* First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed wi...

2026-09-07 17:42 3387

Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain

CAMBRIDGE, Mass., Sept. 2, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clini...

2026-09-03 08:30 3372

Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths

CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clini...

2026-08-17 20:30 4721

Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clini...

2026-08-12 20:30 3025

Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates

CAMBRIDGE, Mass., Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clini...

2026-08-11 17:45 2995

Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science

Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a...

2026-07-30 21:00 3398

Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma

* FDA Fast Track Designation (FTD)

2026-07-29 20:30 3493

Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors

Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor...

2026-07-27 20:00 8806

Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management

* AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaO...

2026-07-22 21:00 5035

Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development

Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and ...

2026-07-15 08:00 4365

Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases

SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage ...

2026-07-13 08:30 4023

Insilico Medicine Releases Positive Profit Alert for the First Half of 2026

CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX...

2026-07-09 08:30 4268

Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

* Potentially first-in-class oral TNIK inhibitor advances into late-stage development after miles...

2026-07-07 21:43 5302

Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic ar...

2026-07-02 10:16 4633

Latest News